Gastroenterology

Volume 168 / Issue 1 January 2025 www.gastrojournal.org

TABLE OF CONTENTS

Contents

ON THE COVER



MYO5B Traffics P-Glycoprotein in Enterocytes. **See article by Dooley, et al, page 84 for additional information.**

COMMENTARIES

1 **Hacking Death in Dublin**
S. O'Mahony

MENTORING, EDUCATION, AND TRAINING CORNER

4 **Building Your Professional Brand: Tips for Early Career Faculty**
J. A. Trieu, A. Kahn, E. S. Aby, and M. Bilal

EDITORIALS

8 **It Runs in the Family: What Studying Unaffected Individuals in Simplex and Multiplex Families Tells Us About Inflammatory Bowel Disease Development**
J. J. Rudbaek, A. Sazonovs, and T. Jess
See Olivera PA et al on page 99.

10 **Where Do Noninvasive Colorectal Cancer Tools "FIT" Alongside Colonoscopy in the Surveillance of High-Risk Patients?**
K. J. Monahan
See van Wifferen F et al on page 136.

GASTRO CURBSIDE CONSULT

13 **An Unexpected Case of Per-rectal Bleeding**
J. Shembrey, C. Cosgrave, and N. Heerasing

17 **Hidden Footprints in Ascites: Lessons From a Mystery Enduring for 200 Years**
Y. Nakatsu, M. Furihata, and T. Osada

V Video CGH Related article in *CGH* Hot Papers From New Investigators

CME CME quiz E Editorial accompanies this article WWW Additional online content available COV Cover

Publisher: *Gastroenterology* **(ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc, 230 Park Avenue, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 450 Fame Avenue, Hanover, PA 17331, USA. 2025 US subscription rates: individual, $848.00; student and resident, $323.00. Outside of the U.S. and possessions: individual, $1026.00; student and resident, $596.00; surface delivery, no additional charge; air mail delivery, add $78.00. Prices subject to change without notice.**

TABLE OF CONTENTS

ELECTRONIC *GASTRO* CURBSIDE CONSULT

For a full list, please see the table of contents online at www.gastrojournal.org.

GASTRO GRAND ROUNDS

21 **Immune Checkpoint Inhibitor–Induced Colitis**
A. S. Thomas, Y. Lu, M. Campbell, J. A. Thompson, D. Tan, D. M. Faleck, and Y. Wang

REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

29 (WWW) **Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease**
A. R. Bourgonje, R. C. Ungaro, S. Mehandru, and J.-F. Colombel

ORIGINAL RESEARCH

Full Reports

Stomach

53 (WWW) **Unveiling Cancer-Related Metaplastic Cells in Both *Helicobacter pylori* Infection and Autoimmune Gastritis**
S. G. Hoft, M. Brennan, J. A. Carrero, N. M. Jackson, C. A. Pretorius, T. M. Bigley, J. B. Sáenz, and R. J. DiPaolo

Helicobacter pylori infection and autoimmune gastritis give rise to similar metaplastic cell phenotypes. One metaplastic subtype, common to both settings, resembles incomplete intestinal metaplasia and transcriptionally relates to gastric cancer.

Small Bowel

68 (WWW) **Glutamine Supplementation as a Novel Metabolic Therapeutic Strategy for *LIG3*-Dependent Chronic Intestinal Pseudo-Obstruction**
C. Diquigiovanni, N. Rizzardi, E. Cataldi-Stagetti, L. Gozzellino, F. Isidori, F. Valenti, A. Orsini, A. Astolfi, T. Giangregorio, L. Pironi, E. Boschetti, S. Arrigo, A. Maresca, P. Magnoni, A. Costanzini, V. Carelli, M. Taniguchi-Ikeda, R. Fato, C. Bergamini, R. De Giorgio, and E. Bonora

This study elucidates the molecular changes in *LIG3*-dependent chronic intestinal pseudo-obstruction. Supplementation with L-glutamine was beneficial for *LIG3*-mutant cells and patients, providing a proof of concept for ad hoc trials with L-glutamine in *LIG3*-mutant patients.

84 (WWW) (COV) **Myosin Vb Traffics P-Glycoprotein to the Apical Membrane of Intestinal Epithelial Cells**
S. A. Dooley, E. Kolobova, A. Burman, I. Kaji, J. R. Digrazia, R. Stubler, A. Goldstein, C. Packirisamy, A. W. Coutts, M. Saqui-Salces, N. Gao, M. A. Engevik, M. D. Shub, J. R. Goldenring, and A. C. Engevik

The authors use animal models, human biopsy samples, and human cells to demonstrate that MYO5B traffics the drug transporter P-glycoprotein to the apical membrane of intestinal epithelial cells.

Inflammatory Bowel Disease

99 (E) (WWW) **Healthy First-Degree Relatives From Multiplex Families vs Simplex Families Have Higher Subclinical Intestinal Inflammation, a Distinct Fecal Microbial Signature, and Harbor a Higher Risk of Developing Crohn's Disease**
P. A. Olivera, H. Martinez-Lozano, H. Leibovitzh, M. Xue, A. Neustaeter, O. Espin-Garcia, W. Xu, K. L. Madsen, D. S. Guttman, C. N. Bernstein, B. Yerushalmi, J. S. Hyams, M. T. Abreu, J. K. Marshall, I. Wrobel, D. R. Mack, K. Jacobson, A. Bitton, G. Aumais, R. Panacionne, L. A. Dieleman, M. S. Silverberg, A. H. Steinhart, P. Moayyedi, D. Turner, A. M. Griffiths, W. Turpin, S.-H. Lee, and K. Croitoru, for the Crohn's and Colitis Canada (CCC) Genetic, Environmental, Microbial (GEM) Project Research Consortium

See editorial on page 8.

In families with multiple cases of Crohn's disease, unaffected members are 3 times more likely to develop the disease, possibly due to environmental factors rather than genetics.

GI Bleeding

111 **Detection of Gastrointestinal Bleeding With Large Language Models to Aid Quality Improvement and Appropriate Reimbursement**
N. S. Zheng, V. K. Keloth, K. You, D. Kats, D. K. Li, O. Deshpande, H. Sachar, H. Xu, L. Laine, and D. L. Shung

Generative artificial intelligence, such as large language models, can accurately detect gastrointestinal bleeding in clinical notes, helping to drive quality improvement initiatives and research to improve our patient care.

Prevention and Early Detection

121 **Stool-Based Testing for Post-Polypectomy Colorectal Cancer Surveillance Safely Reduces Colonoscopies: The MOCCAS Study**
B. Carvalho, W. de Klaver, F. van Wifferen, M. C. J. van Lanschot, A. J. P. van Wetering, Q. E. W. van der Zander, M. Lemmens, A. S. Bolijn, M. Tijssen, P. Delis-van Diemen, N. Buekers, K. Daenen, J. van der Meer, P. G. van Mulligen, B. S. Hijmans, S. de Ridder, L. Meiqari, M. Bierkens, R. W. M. van der Hulst, J. P. H. Kuyvenhoven, A. M. van Berkel, A. C. T. M. Depla, M. E. van Leerdam, J. M. Jansen, C. A. Wientjes, J. W. A. Straathof, E. T. P. Keulen, D. Ramsoekh, L. M. G. Moons, M. Zacherl, A. A. M. Masclee, M. de Wit, M. J. E. Greuter, M. van Engeland, E. Dekker, V. M. H. Coupé, and G. A. Meijer

Stool-based surveillance strategies were identified that may safely reduce the number of post-polypectomy surveillance colonoscopies. Multitarget stool DNA–based surveillance was more costly than colonoscopy surveillance, and fecal immunochemical test–based surveillance saved costs compared with colonoscopy surveillance.

136 **Combining Colonoscopy With Fecal Immunochemical Test Can Improve Current Familial Colorectal Cancer Colonoscopy Surveillance: A Modelling Study**
F. van Wifferen, M. J. E. Greuter, M. E. van Leerdam, M. B. W. Spanier, E. Dekker, H. F. A. Vasen, I. Lansdorp-Vogelaar, K. Canfell, G. A. Meijer, T. M. Bisseling, N. Hoogerbrugge, and V. M. H. Coupé

See editorial on page 10.

Fecal immunochemical test could play an important role in surveillance for individuals with a family history of colorectal cancer. Ten-yearly colonoscopy and 2-yearly fecal immunochemical test between colonoscopies from ages 40 to 80 years was the optimal strategy.

RESEARCH LETTERS

150 **Development and Validation of an Integrative Risk Score for Future Risk of Crohn's Disease in Healthy First-Degree Relatives: A Multicenter Prospective Cohort Study**
S.-H. Lee, W. Turpin, O. Espin-Garcia, W. Xu, K. Croitoru, and Crohn's and Colitis Canada-Genetic, Environmental, Microbial (CCC-GEM) Project Research Consortium

154 **Pragmatic Resect and Discard Implementation Using Computer-Assisted Optical Polyp Diagnosis**
M. Taghiakbari, D. K. Rex, H. Pohl, R. Djinbachian, F. Huang, C. Hassan, and D. von Renteln

157 **Proteomic Biomarkers in Serum Predict Villous Atrophy Development in Asymptomatic Potential Celiac Disease Children at Time of Diagnosis**
R. Auricchio, R. Mandile, J. Samsom, C. Esposito, R. de Cegli, L. Greco, and European Laboratory for Food Induced Disease (ELFID) Group

160 **Dual Targeting of Syndecan-1 and Glucose Transporter-1 With a Novel Lipid-Based Delivery System Enhances Therapeutic Efficacy and Overcomes Chemoresistance in Pancreatic Ductal Adenocarcinoma**
H. K. Rachamala, N. M. R. Nakka, R. S. Angom, S. Bhattacharya, K. Pal, and D. Mukhopadhyay

CLINICAL PRACTICE UPDATES

164 **AGA Clinical Practice Update on Endoscopic Enteral Access: Commentary**
D. Micic, J. A. Martin, and J. Fang

169 **AGA Clinical Practice Update on Nonampullary Duodenal Lesions: Expert Review**
V WWW *M. J. Bourke, S. K. Lo, R. C. D. Buerlein, and K. K. Das*

GASTRO DIGEST

176 **Integrated Telemedicine to Treat HCV Through Opioid Treatment Programs**
C. Mezzacappa

176 **Treating Chronic Pancreatitis Pain With the Use of Extracorporeal Shock-Wave Lithotripsy and Endoscopy**
M. Hanscom

177 **Longitudinal Gut Microbiome Shifts Correlate With Clinical Outcomes of Immune Checkpoint Inhibitors–Treated Melanoma: Time for Microbial Biomarkers in Oncology?**
G. Ianiro

178 **The Brain and the Immune System: A Dynamic Duo in Detecting and Defending**
L. Y. Hung and K. G. Margolis

CORRESPONDENCE

180 **Glucagon-like Peptide 1 Receptor Agonists and Postendoscopic Aspiration Pneumonia: What Plays a Role in Clinical Practice?**
H. Xu and L. Lin

180 **Do Glucagon-like Peptide 1 Receptor Agonists Cause Postendoscopic Aspiration Pneumonia?**
P. Hartmann

181 **Glucagon-like Peptide 1 Receptor Agonists and Risk of Adverse Anesthesia Events: Caution Warranted When Interpreting Associations With Pulmonary Aspiration**
I. Zandvakili, W.-W. Hsu, and G. G. Ginsberg

183 **With Great Statistical Power Comes Great Responsibility: Pitfalls of Claims Database Research on the Periprocedural Glucagon-like Peptide 1 Receptor Agonist Management Debate**
B. Hiramoto, T. R. McCarty, M. Muftah, and W. W. Chan

184 **Measuring the Quality and Safety of Upper Endoscopy in Patients Taking Glucagon-like Peptide 1 Receptor Agonists**
R. Bansal, R. Khan, and S. C. Grover

185 **Reply**
A. Rezaie and Y. H. Yeo

186 **Comments on "Diagnosis and Management of Pancreatic Cysts"**
S. S. Vege

186 **Reply**
T. B. Gardner, W. G. Park, and P. J. Allen

187 **Comments on "Thoracoabdominal Wall Motion–Guided Biofeedback Treatment of Abdomina Distention: A Randomized Placebo-Controlled Trial"**
P. Iovino, M. C. Neri, L. D'alba, A. Santonicola, S. L. Popa, and G. Chiarioni

188 **Methodological Aspects of "Thoracoabdominal Wall Motion–Guided Biofeedback Treatmer of Abdominal Distention: A Randomized Placebo-Controlled Trial"**
M. K. Goyal, K. Sachdeva, and O. Goyal

189 **Refining Biofeedback in Gastroenterology: Enhancing Precision in Thoracoabdominal Motion Studies**
J. Zhu

190 **Advancing Biofeedback Therapy in Abdominal Distention: Recommendations for Methodological Improvements and Increased Generalizability**
X. Guo, Y. Wang, and Y. Yuan

191 **Focus on Psychological Intervention: Insights From Thoracoabdominal Wall Motion–Guided Biofeedback Treatment of Abdominal Distention**
C. Tian, C. Zhai, and H. Pan

192 **Reply**
F. Azpiroz

193 **Corrigendum**